{
    "Trade/Device Name(s)": [
        "LZI Cannabinoids (cTHC) Enzyme Immunoassay",
        "LZI Cannabinoids (cTHC) Drugs of Abuse (DAU) Calibrators",
        "LZI Cannabinoids (cTHC) Drugs of Abuse (DAU) Controls"
    ],
    "Submitter Information": "Lin-Zhi International, Inc.",
    "510(k) Number": "K110239",
    "Predicate Device Reference 510(k) Number(s)": [
        "K021887",
        "K021449"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "LDJ",
        "DLJ",
        "LAS"
    ],
    "Summary Letter Date": "June 08, 2011",
    "Summary Letter Received Date": "June 08, 2011",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21CFR862.3870",
        "21CFR862.3200",
        "21CFR862.3280"
    ],
    "Regulation Name(s)": [
        "Cannabinoid Test System"
    ],
    "Analyte Class(es)": [
        "toxicology"
    ],
    "Analyte(s)": [
        "11-nor-\u03949-THC-9-COOH (cTHC)",
        "Cannabinoids"
    ],
    "Specimen Type(s)": [
        "Human urine"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Automated clinical chemistry analyzers"
    ],
    "Method(s)/Technology(ies)": [
        "Homogeneous enzyme immunoassay"
    ],
    "Methodologies": [
        "Enzyme immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Calibrator",
        "Control",
        "Kit"
    ],
    "Document Summary": "FDA 510(k) summary for LZI Cannabinoids (cTHC) enzyme immunoassay, calibrators, and controls for qualitative and semi-quantitative detection of cannabinoids in human urine",
    "Indications for Use Summary": "Intended for qualitative and semi-quantitative determination of cannabinoids in human urine using cTHC calibrator at cutoff values of 25, 50, or 100 ng/mL; for use with automated clinical chemistry analyzers and in laboratory procedures including specimen dilution for confirmation and quality control",
    "fda_folder": "Toxicology"
}